The Priority Review

Tag

Hepatitis B

3 stories

Stories

  1. Regulation

    FDA releases final guidance on reducing transfusion-transmitted Hepatitis B virus

    FDA announces availability of the final guidance titled "Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus" on November 3, 2026. The guidance supersedes several earlier documents and applies to the collection of Whole Blood and blood components, including Source Plasma.

  2. Approvals

    FDA approves Hibsago for certain adults with chronic hepatitis B

    Across pooled Phase 3 trials, 19% of Hibsago recipients met GSK's functional-cure measure 24 weeks after stopping treatment. FDA approval adds Hibsago with existing antiviral therapy for eligible adults without cirrhosis.

  3. Clinical trials

    PT Bio Farma registers Phase 3 trial of in-house recombinant Hepatitis B vaccine at birth dose

    This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 270 participants and has a planned start date of October 2026 with a planned primary completion date of February 2027.